About Multiple Sclerosis Foundation



Home > Learn About Multiple Sclerosis > News > New drug candidate shows promise in treating MS

New drug candidate shows promise in treating MS

9/22/2014

The results of a new drug candidate showed a reduced relapse rate and lower levels of new brain damage in MS patients. The drug also shows higher levels of safety for patients.

The drug candidate RPC1063, first discovered and synthesized at the Scripps Research Institute, was tested during a six-month Phase 2 study of 258 multiple sclerosis patients. The results of the drug candidate showed a reduction in the relapse rate by up to 53 percent and decreased new brain damage by more than 90 percent in MS patients. The drug also showed a strong safety profile with nearly all participants staying on the drug regimen during the trial period.

Receptos, a San Diego biopharmaceutical company, is developing RPC1063 for approval by the U.S. Food and Drug Administration. The drug candidate is currently in a Phase 3 randomized, double-blind study involving 1,200 relapsing multiple sclerosis patients. The trial is expected to be completed in 2017.

“These data support our labs’ approach at TSRI that discovery of fundamental mechanisms in chemical biology provides the foundation for intelligent intervention in disease processes,” said Ed Rosen, Scripps California.

The new RPC1063 findings were presented at the MS Boston 2014 meeting.



  Support the MSF
Supporting MSF's programs to help make "a brighter tomorrow" has never been easier.
make a donation 

  Learn About MS
Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression.
learn more 

 

Unless otherwise specified, all medical content is compiled by MSF staff and reviewed for accuracy by a member of our Medical Advisory Board.

The MSF strives to present clear and unbiased information. This site is partially funded through a grant from Bayer Healthcare, LLC.

© Copyright 2000-2013 Multiple Sclerosis Foundation - All Rights Reserved

�